Hims(US:HIMS) Prnewswireยท2025-06-27 14:00Core Viewpoint - Hims & Hers Health, Inc. is under investigation for potential securities fraud and unlawful business practices following the termination of its partnership with Novo Nordisk, which has raised concerns about patient safety and compliance with legal regulations [1][2]. Group 1: Company Developments - Novo Nordisk announced the discontinuation of its partnership with Hims & Hers, ending direct access to the Wegovy weight loss drug due to non-compliance with regulations regarding the sale of compounded drugs [2]. - Following the announcement, Hims & Hers' stock price experienced a significant decline, falling by $22.24 per share, or 34.63%, closing at $41.98 per share on June 23, 2025 [3]. Group 2: Legal and Regulatory Issues - Pomerantz LLP is investigating claims on behalf of investors regarding potential securities fraud or other unlawful business practices by Hims & Hers and its officers or directors [1].